Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
MAZE
MAZE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MAZE News
Wall Street Analysts Adjust Ratings on Key Stocks
19h ago
Benzinga
Chronic Kidney Disease Market Growth Drivers
Mar 03 2026
Newsfilter
a16z Capital Management Acquires Navan Shares
Feb 18 2026
Fool
a16z Capital Management Acquires Navan Shares
Feb 18 2026
NASDAQ.COM
Maze Therapeutics Executive Sells Stock Options
Feb 16 2026
Fool
Maze Therapeutics Executive Sells Shares
Feb 16 2026
NASDAQ.COM
Analysis of Maze Therapeutics Executive Stock Transaction
Feb 01 2026
Fool
Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year
Feb 01 2026
Yahoo Finance
Maze Therapeutics Stock Surges 157% in 2025
Feb 01 2026
NASDAQ.COM
MAZE Options Analysis: $40 Put Option Offers 9% Potential YieldBoost
Jan 21 2026
NASDAQ.COM
Maze Therapeutics' Atul Dandekar Sells 72,500 Shares for $2.94 Million
Jan 08 2026
Fool
Maze Therapeutics Insider Sells 72,500 Shares for $2.94 Million
Jan 08 2026
NASDAQ.COM
Maze Therapeutics CEO to Present at J.P. Morgan Healthcare Conference on January 12
Jan 05 2026
Globenewswire
MAZE Surpasses Average Analyst Expectations
Dec 04 2025
NASDAQ.COM
Wedbush Reaffirms Outperform Rating for Maze Therapeutics (MAZE)
Nov 08 2025
NASDAQ.COM
Biotech Stocks Reach 52-Week Peaks: MTSR, INSM, ABVX, and MAZE Drive Surge on October 30
Oct 31 2025
NASDAQ.COM
Show More News
